Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06203444 · ClinicalTrials.gov registry record · Phase 1
An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females
A Phase 1 study, sponsored by Ardelyx.
- Completed
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
NCT06203444 is a Phase 1 study that has completed, run by Ardelyx. The registered enrollment target is 7 participants.
The verdict
NCT06203444, a Phase 1 study, has completed, sponsored by Ardelyx.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
Study Summary
This is an open label study to investigate PK of tenapanor and AZ13792925 in breast milk of lactating female subjects.
Interventions
- DRUG Tenapanor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2023-11-27 |
| Est. Completion | 2024-05-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06203444
The ClinicalTrials.gov registry entry for NCT06203444 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ardelyx, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tenapanor is the first listed.
NCT06203444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06203444 about?
NCT06203444 is a clinical study titled "An Open-label Study to Evaluate the Pharmacokinetics of Oral Tenapanor in Breast Milk of Lactating Females". This is an open label study to investigate PK of tenapanor and AZ13792925 in breast milk of lactating female subjects.
What is the current status of trial NCT06203444?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2023-11-27. Estimated completion is 2024-05-30.
What interventions are being tested in trial NCT06203444?
The interventions under investigation include: Tenapanor (DRUG).
Who is sponsoring clinical trial NCT06203444?
This trial is sponsored by Ardelyx, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.